Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006009
Recruitment Status : Completed
First Posted : October 8, 2003
Last Update Posted : May 15, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced or recurrent lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Small Intestine Cancer Biological: visilizumab Phase 1

Detailed Description:


  • Determine the safety and tolerability of monoclonal antibody HuM291 in patients with advanced or recurrent CD3+ T-cell lymphomas.
  • Evaluate the pharmacokinetics and pharmacodynamics of this treatment regimen in this patient population.
  • Determine the response in these patients treated with this regimen.

OUTLINE: This is a dose-escalation study.

Patients receive monoclonal antibody HuM291 IV over 3 hours on days 1-4 in the absence of unacceptable toxicity. Patients achieving a partial response, complete response with recurrence, or stable disease may receive further therapy.

Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuM291 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed weekly for 1 month and then monthly for 3 months.

PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase I, Multiple Dose Escalation Trial of Intravenous Humanized Anti-CD3 Antibody (HuM291) in Patients With CD3+ T-cell Lymphomas
Study Start Date : April 2001
Actual Study Completion Date : October 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed CD3+ T-cell lymphoma for which no standard curative therapy exists

    • Peripheral T-cell lymphoma

      • Recurrent and/or progressive disease after at least 1 prior therapy
    • Mycosis fungoides

      • Stage IB/IIA

        • Recurrent and/or progressive disease after at least 2 prior therapies
      • Stage IIB-IVB

        • Recurrent and/or progressive disease after at least 1 prior therapy
    • All other T-cell lymphomas

      • Recurrent and/or progressive disease after at least 1 prior therapy
  • Evaluable disease

    • Any nodal site or mass lesion at least 1.5 cm in longest axis on physical exam or CT scan
    • Skin lesions at least 1 cm in longest axis for cutaneous lymphoma
  • High numbers of circulating T-cells allowed



  • 18 and over

Performance status:

  • ECOG 0-2
  • Karnofsky 50-100%

Life expectancy:

  • Not specified


  • WBC at least 2,000/mm^3*
  • Absolute neutrophil count at least 1,000/mm^3*
  • Platelet count at least 75,000/mm^3* NOTE: * Unless due to lymphoma


  • Bilirubin no greater than 2.0 times normal*
  • AST/ALT no greater than 2.5 times upper limit of normal*
  • Hepatitis B and C negative NOTE: * Unless due to lymphoma


  • Not specified


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • No other uncontrolled illness
  • No ongoing or active infection
  • No other active malignancies except basal cell skin cancer or carcinoma in situ of the cervix
  • HIV-1 negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • See Disease Characteristics

Biologic therapy:

  • At least 60 days since prior humanized or chimeric antibody therapy


  • At least 3 weeks since prior chemotherapy

Endocrine therapy:

  • Not specified


  • At least 3 weeks since prior radiotherapy


  • Not specified


  • At least 30 days since prior investigational drugs or therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00006009

Layout table for location information
United States, California
Stanford University Medical Center
Stanford, California, United States, 94305-5408
Sponsors and Collaborators
Stanford University
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Youn H. Kim, MD Stanford University

Layout table for additonal information Identifier: NCT00006009    
Other Study ID Numbers: SUMC-NCI-102
CDR0000068017 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: October 8, 2003    Key Record Dates
Last Update Posted: May 15, 2013
Last Verified: April 2003
Keywords provided by National Cancer Institute (NCI):
stage I cutaneous T-cell non-Hodgkin lymphoma
stage II cutaneous T-cell non-Hodgkin lymphoma
stage III cutaneous T-cell non-Hodgkin lymphoma
stage IV cutaneous T-cell non-Hodgkin lymphoma
recurrent cutaneous T-cell non-Hodgkin lymphoma
small intestine lymphoma
stage III adult T-cell leukemia/lymphoma
stage IV adult T-cell leukemia/lymphoma
recurrent adult T-cell leukemia/lymphoma
angioimmunoblastic T-cell lymphoma
anaplastic large cell lymphoma
stage I mycosis fungoides/Sezary syndrome
stage II mycosis fungoides/Sezary syndrome
stage III mycosis fungoides/Sezary syndrome
stage IV mycosis fungoides/Sezary syndrome
recurrent mycosis fungoides/Sezary syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Immunologic Factors
Physiological Effects of Drugs